{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tbo-filgrastim", "query": { "intervention": "tbo-filgrastim" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 942, "total_pages": 95, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tbo-filgrastim&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-16T10:28:49.857Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00002126", "title": "A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Cytopenias" ], "interventions": [ { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 250, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-16T10:28:49.857Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002126" }, { "nct_id": "NCT00003243", "title": "Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": "1998-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-03-10", "last_synced_at": "2026-09-16T10:28:49.857Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003243" }, { "nct_id": "NCT00017368", "title": "Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "etoposide phosphate", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "isotretinoin", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 42, "start_date": "2001-04", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2014-02-13", "last_synced_at": "2026-09-16T10:28:49.857Z", "location_count": 8, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Portland, Oregon + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00017368" }, { "nct_id": "NCT00521014", "title": "GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 14, "start_date": "2007-10", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2015-12-22", "last_synced_at": "2026-09-16T10:28:49.857Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00521014" }, { "nct_id": "NCT07186179", "title": "Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diamond Blackfan Anemia" ], "interventions": [ { "name": "Mobilization Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "3 Years to 30 Years" }, "enrollment_count": 10, "start_date": "2026-06-01", "completion_date": "2027-04-01", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-09-16T10:28:49.857Z", "location_count": 1, "location_summary": "New Hyde Park, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07186179" }, { "nct_id": "NCT00152100", "title": "Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Severe Combined Immunodeficiency" ], "interventions": [ { "name": "Stem cell transplant", "type": "PROCEDURE" }, { "name": "Filgrastim, Alemtuzumab", "type": "DRUG" }, { "name": "Miltenyi CliniMACS", "type": "DEVICE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "DEVICE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "2 Years", "sex": "ALL", "summary": "Up to 2 Years" }, "enrollment_count": 4, "start_date": "2004-02", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2009-05-20", "last_synced_at": "2026-09-16T10:28:49.857Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00152100" }, { "nct_id": "NCT01707004", "title": "Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "de Novo Myelodysplastic Syndromes", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "decitabine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2013-05-16", "completion_date": "2017-10-07", "has_results": true, "last_update_posted_date": "2019-11-21", "last_synced_at": "2026-09-16T10:28:49.857Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01707004" }, { "nct_id": "NCT01146834", "title": "Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "bortezomib (Velcade)", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Plerixafor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2011-03", "completion_date": "2019-02-04", "has_results": true, "last_update_posted_date": "2019-12-27", "last_synced_at": "2026-09-16T10:28:49.857Z", "location_count": 5, "location_summary": "Atlanta, Georgia • New York, New York", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01146834" }, { "nct_id": "NCT00002798", "title": "Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Childhood Acute Erythroleukemia (M6)", "Childhood Acute Megakaryocytic Leukemia (M7)", "Childhood Acute Monoblastic Leukemia (M5a)", "Childhood Acute Monocytic Leukemia (M5b)", "Childhood Acute Myeloblastic Leukemia With Maturation (M2)", "Childhood Acute Myeloblastic Leukemia Without Maturation (M1)", "Childhood Acute Myelomonocytic Leukemia (M4)", "Childhood Myelodysplastic Syndromes", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndromes", "Refractory Anemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Refractory Anemia With Ringed Sideroblasts", "Secondary Myelodysplastic Syndromes", "Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies" ], "interventions": [ { "name": "asparaginase", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "idarubicin", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "thioguanine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 880, "start_date": "1996-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-09-16T10:28:49.857Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002798" }, { "nct_id": "NCT00873093", "title": "Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-cell Adult Acute Lymphoblastic Leukemia", "B-cell Childhood Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Lymphoblastic Lymphoma", "T-cell Adult Acute Lymphoblastic Leukemia", "T-cell Childhood Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "L-asparaginase", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "pegaspargase", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "etoposide phosphate", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "High Dose MTX", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "31 Years", "sex": "ALL", "summary": "1 Year to 31 Years" }, "enrollment_count": 148, "start_date": "2009-03", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2017-01-27", "last_synced_at": "2026-09-16T10:28:49.857Z", "location_count": 157, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 124 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00873093" } ] }